PHARMACEUTICAL COMPOSITION FOR GROWTH HORMONE DEFICIENCY THERAPY COMPRISING FUSED hGH PROTEIN

摘要

FIELD: biotechnology. ;SUBSTANCE: present invention relates to the area of biotechnology, specifically to a therapeutic fused protein based on human growth hormone and compositions thereof and can be used in growth hormone deficiency therapy. The proposed hGH GX-H9 fused protein comprises human growth hormone and hybrid Fc. Fused hGH GX-H9 protein is administered to the patient once a week at a dosage of 0.4 to 1.6 mg/kg per kg of the body weight of the patient or once every two weeks at a dosage of 0.8 to 3.2 mg/kg per kg of the body weight of the patient.;EFFECT: invention ensures extended time of presence of growth hormone in vivo so that the IGF-1 SDS value is maintained within the normal range for a long period of time.;9 cl, 10 dwg, 5 tbl, 5 ex